Publications by authors named "D Krasowska"
: The risk of asthma in patients with psoriasis and that of psoriasis in patients with asthma have increased, but relevant data for the pediatric population are lacking. Therefore, we performed a meta-analysis to assess the pooled association between psoriasis and asthma in children and adolescents. : We conducted an extensive search of the medical literature databases through to July 2024.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the demographic and clinical traits of Polish patients with generalized pustular psoriasis (GPP), revealing that most patients are middle-aged women with common comorbidities like hypertension and cardiovascular diseases.
- A total of 90 patients were examined, who had a median GPP duration of 3 years and experienced an average of 2 flares, often requiring hospitalization; main triggers for flares included medications and infections.
- The findings showed significant differences, such as younger patients often having GPP alongside psoriasis vulgaris (PV), highlighting a need for better management due to the high hospitalization rate and recurrent flares.
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by inflammation, progressive vasculopathy, and fibrosis of skin and internal organs. The aim of the study was to evaluate extended inflammatory parameters (EIP) in patients with SSc in comparison to the control group of healthy subjects.
Methods: A total of 28 patients with SSc and 29 healthy controls (HCs) were included in the study.
Article Synopsis
- * The trials involved adult and adolescent participants with moderate-to-severe atopic dermatitis and were conducted across 22 countries, comparing the effects of 30 mg of nemolizumab versus a placebo alongside topical corticosteroids.
- * Key measures included improvements in skin clear-up (IGA score) and eczema severity (EASI-75), as well as pruritus and sleep disturbances at various intervals, with outcomes assessed through masked evaluators.
Background: Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).
Methods: A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (ie mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity % predicted (ppFVC) were assessed for up to 5 years follow-up comparing patients who started early (disease duration ≤ 3 years) vs late with immunosuppression.